Work

AB0472 Pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA)

Year: 2018

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2018-eular.1375

Authors: T. Ishii, Y. Sato, Y. Munakata, M. Kajiwara, Y. Takahashi, F. Anwar, A. Paccaly, P. Kovalenko, J. Parrino, A. Boyapati, C. Xu

Institutions: Tohoku University Hospital, Sanofi (Japan), Sanofi (United States), Regeneron (United States)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Celgene, Regeneron Pharmaceuticals, Celltrion, Genentech, Samsung, EMD Serono

OpenAlex ID: W2903028892

Cites:

Cited by: 6

Related to: 10